ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4352-4364

  Pedram, Ali ^b   Razandi, Mahnaz ^a   Korach, Kenneth S ^c   Narayanan, Ramesh ^e   Dalton, James T ^d   Levin, Ellis R ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d GTx Inc   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BETA LGND2; ESTRADIOL; ESTROGEN RECEPTOR BETA; GLYCOGEN SYNTHASE KINASE 3BETA; HORMONE RECEPTOR STIMULATING AGENT; MESSENGER RNA; PROTEIN KINASE B; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC HYPERTENSION;

ANGIOTENSINS; ANIMALS; CARDIOMEGALY; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; HEART; ISOQUINOLINES; MICE; MYOCARDIUM; OVARIECTOMY; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84886482116     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1358     Document Type: Article

References (53)

1. Kim J, Levin ER. Estrogen signaling in the cardiovascular system. Nucl Recept Signaling. 2006;4:e013-e017.
2. Xin HB, Senbonmatsu T, Cheng DS, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature. 2002;416: 334-338.
3. Molkentin JD, Lu JR, Antos CL, et al.Acalcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93: 215-228.
4. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. J Biol Chem. 2003;278: 36981-36984.
5. Pedram A, Razandi R, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro: antagonism of calcineurin-related hypertrophy through Induction of MCIP1. J Biol Chem. 2005; 280: 26339-26348.
6. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor β to inhibit calcineurin. Endocrinology. 2008;149: 3361-3369.
7. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117: 568-575.
8. Pedram A, Razandi M, O'Mahony F, Lubahn D, Levin ER. Estrogen receptor β prevents cardiac fibrosis. Mol Endocrinol. 2010;24: 2152-2165.
9. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 2001;104: 2300-2304.
10. Lindenfeld J, Ghali JK, Krause-Steinrauf, HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol. 2003;42: 1238-1245.
11. Reis SE, Holubkov R, Young JB, Whie BG, Cohn JN, Feldman AM. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the Vesnarinone studies. J Am Coll Cardiol. 2000;36: 529-533.
12. Light KC, Hinderliter AL, West SG, et al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J Hypertens. 2001;19: 269-278.
13. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 2006;6: 360-368.
14. Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol. 2004;50: 3-22.
15. Yepuru M, Eswaraka J, Kearby JD, et al. Estrogen receptor β selective ligands alleviate high-fat diet and ovariectomy-induced obesity in mice. J Biol Chem. 2010;285: 31292-31303.
16. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA. 1998;95: 15677-15682.
17. Bergman I, Loxley, R. New spectrophotometric method for the dedoi termination of proline in tissue hydrolyzates. Anal Chem. 1970;42: 702-706.
18. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008;22: 2448-2465.
19. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Thiem NV, Swynghedauw B. Myosin isozymes redistribution in chronic heart overloading. Nature. 1979;282: 105-107.
20. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339: 321-328.
21. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clin Exp Pharmacol Physiol. 2004;31: 791-794.
22. Wang L, Proud CG. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor antagonists in adult cardiomyocytes. Circ Res. 2002;91: 821-829.
23. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2001;98: 3328-3333.
24. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J Biol Chem. 2002;277: 30401-30407.
25. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase- 3β suppresses cardiac hypertrophy in vivo. Proc Nat Acad Sci USA. 2002;99: 907-912.
26. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res. 2003;92: 1079-1088.
27. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, Sadoshima J. Glycogen synthase kinase 3β regulates GATA4 in cardiac myocytes. J Biol Chem. 2001;276: 28586-28597.
28. Charron F, Paradis P, Bronchain O, Nemer G, Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol. 1999;19: 4355-4365.
29. Trivedi CM, Luo Y, Yin Z, et al. HDAC2 regulates the cardiac hypertrophic response by modulating GSK3β activity. Nat Med. 2007;13: 234-331.
30. MinagawaT, Ijuin T, Mochizuki Y,TakenawaT. Identification and characterization of a sac domain-containing phosphoinositide 5-phosphatase. J Biol Chem. 2001;276: 22011-22015.
31. Higaki J, Aoki M, Morishita R, et al. In vivo evidence of the importance of cardiac angiotensin-converting enzyme in the pathogenesis of cardiac hypertrophy. Arterioscler Thromb Vasc Biol. 2000;20: 428-434.
32. Jacobi J, Schlaich MP, Delles C, Schobel HP, Schmieder RE. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens. 1999; 12: 418-422.
33. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012;9: 276-285.
34. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science. 2002;295: 505-508.
35. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91: 1103-1113.
36. Izumiya Y, Araki S, Usuku H, Rokutanda T, Hanatani S, Ogawa H. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med. 2012;2012:246058.
37. González A, López B, Díez J. Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Med Clin North Am. 2004;88: 83-97.
38. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction.AmJ Physiol Heart Circ Physiol. 2003;284:H1560-H1569.
39. Satoh M, Matter CM, Ogita H, et al. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation. 2007;115: 3197-3204.
40. Jazbutyte V, Arias-Loza PA, Hu K, et al. Ligand-dependent activation of ER lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized SHR. Cardiovasc Res. 2008;77: 774-781.
41. Nadadur RD, Umar S, Wong G, et al. Reverse right ventricular structural and extracellular matrix remodeling by estrogen in severe pulmonary hypertension. J Appl Physiol. 2012;113: 149-158.
42. Paulin R, Michelakis ED. The estrogen puzzle in pulmonary arterial hypertension. Circulation. 2012;126: 1016-1019.
43. Lim WK, Wren B, Jepson N, Roy S, Caplan G. Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol. 1999;83: 1132-1134.
44. Miya Y, Sumino H, Ichikawa S, et al. Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hypertens Res. 2002;25: 153-159.
45. Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol. 1999; 31: 395-403.
46. Sorescu D. Smad3 mediates angiotensin II and TGF-β1-induced vascular fibrosis: Smad3 thickens the plot. Circ Res. 2006;98: 988-989.
47. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice. Proc Natl Acad Sci USA. 2002;99: 4586-4591.
48. Wilkins BJ, De Windt LJ, Bueno OF, et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurinmediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22: 7603-7613.
49. Klinger JR, Warburton RR, Pietras L, et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2002; 282:H58-H65.
50. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS.Amouse model of angiotensin II slow pressor response: role of oxidative stress.JAm Soc Nephrol. 2002;13: 2860-2868.
51. Brede M, Roell W, Ritter O, et al. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension. 2003;42: 1177-1182.
52. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors α and β. J Biol Chem. 2005; 280: 19704-19710.
53. Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal rennin-angiotensin systems: mechanism of cardiovascular and renal effects. J Investig Med. 2007;55: 341-359.